ERBB2 is overexpressed in 20–30% of breast cancers, and the monoclonal antibody Trastuzumab (Herceptin) that targets ERBB2 has been used with success to treat these (Slamon et al, 2001). The gene discussed is ERBB2; the disease is breast cancer.